Unbiased metagenomic detection of RNA viruses for rapid identification of viral pathogens in clinical samples

Anthony D. Kappell^{1*}, Amanda N. Scholes¹, Matthew B. Scholz¹, Nicolette C. Keplinger¹, Leah
 W. Allen¹, Matthew C. Murray¹, Krista L. Ternus¹ and F. Curtis Hewitt¹

- ³ ¹ Signature Science, LLC, Austin, Texas, United States of America
- 4 * Correspondence:
- 5 Corresponding Author
- 6 akappell@signaturescience.com
- 7 Keywords: Nanopore Sequencing, MinION, RNA Virus, Agnostic Sequencing, Metagenomics,
- 8 Respiratory Pathogens, Blood Pathogens, Coronavirus.

Abstract

9 Unbiased long read sequencing approaches for clinical metagenomic sample analysis holds enormous

- 10 potential for pathogen detection, including improved detection of unknown, novel or emerging
- 11 viruses. However, the rapid rate of development in nanopore sequencing and library preparation
- 12 methods complicates the process of selecting a standardized method for unbiased RNA virus
- 13 detection. Here, we evaluate multiple sequencing approaches to identify a workflow with sufficient 14 sensitivity, limits of detection, and throughput for potential utilization in a clinical laboratory setting.
- Four separate library preparation methods for the Oxford Nanopore Technologies MinION sequencer
- are compared, including direct RNA, direct cDNA, rapid cDNA, and double stranded cDNA. We
- also establish that depletion of host RNA is not required and can be deleterious for viral RNA
- 18 detection in some instances when using samples in viral transport media (VTM) or plasma. Using
- 19 unbiased whole genome amplification following reverse transcription, we achieve limits of detection
- 20 on the order of 1.95E03 GE/mL of Venezuelan Equine Encephalitis Virus (VEEV) spiked in human
- 21 plasma. We also report initial detection of 5.43E06 GE/mL of coronavirus 229E spiked into VTM
- 22 samples containing human background RNA which are expected to decrease significantly during
- 23 upcoming testing. These metrics were achieved within a 6-plex multiplex reaction, illustrating the
- 24 potential to increase throughput and decrease costs for relevant sample analysis. Data analysis was
- 25 performed using EPI2ME Labs framework and open access tools that are readily accessible to most
- clinical laboratories. Taken together, this work describes an optimized method for unbiased nanopore
- 27 sequencing and analysis of RNA viruses present in two common clinical matrices.

28 Introduction

- 29 RNA viruses pose a significant threat to global public health. Beyond the current coronavirus
- 30 pandemic, filoviruses (e.g., ebolaviruses), alphaviruses (e.g., Venezuelan Equine Encephalitis Virus
- 31 (VEEV)), and flaviviruses (e.g., Zika virus), among others, cause recurring outbreaks in the Americas
- 32 and around the world. While transmission pathways and replication numbers vary between them,
- 33 viruses generally form the most transmissible infectious threats, and beyond vaccines, they have
- 34 fewer options for treatment and containment following an outbreak. Spillover of zoonotic diseases
- 35 from animal populations (e.g., bats), which is the likely cause of many recent viral outbreaks,
- 36 presents a continuing threat.

- 37 Unbiased, metagenomic sequence-based approaches could lead to early detection of both previously
- 38 characterized and novel RNA viruses [1]. It has the potential to serve as a hypothesis-free, single, and
- 39 universal assay for diagnostics of known and novel infectious disease and Emerging Infectious
- 40 Diseases (EIDs) directly from samples [2–5]. Metagenomics for pathogen detection in public health
- 41 could overcome many of the current challenges with traditional methods. It offers the power to
- 42 identify novel or divergent pathogens for which there is no other diagnostic test available, as well as
- 43 the ability to more rapidly and cost effectively identify known pathogens. Techniques that require
- serial testing against a list of suspected pathogens or culturing can lead to delayed actionable results
- 45 especially for slow-growing pathogens, such as *Mycobacterium tuberculosis*, while metagenomic
- 46 approaches comprise a single test and are increasing in speed as sequencing technologies advance.
 47 Although performing multiple tests for known pathogens can become very expensive and time
- Although performing multiple tests for known pathogens can become very expensive and time
 consuming, the declining cost of a single metagenomic test makes it more economically justifiable.
- 49 These trends of increasing speed and reduced cost are highlighted by nanopore sequencing, which
- 50 can combine real time sequence analysis with relatively inexpensive, disposable sequencing reagents.
- 51 Nanopore sequencing for public health threats is well established [6–9], and targeted nanopore
- 52 sequencing for viral detection has been successful as part of the COVID-19 pandemic response in
- 53 public health labs [10]. Unlike unbiased metagenomic sequencing, targeted approaches selectively
- 54 amplify specific sections of viral genomes before sequencing. Rapid nanopore metagenomics
- 55 workflows, such as cDNA synthesis and direct RNA sequencing, have been established as a
- 56 foundation for unbiased viral sequencing, but significant work is needed to evaluate and validate the
- 57 best performing methods to enable the implementation of these promising new tools in public health
- 58 labs. In this study, we evaluate methods using the Oxford Nanopore MinION sequencing device to
- 59 detect RNA viruses rapidly and accurately in an unbiased manner. This approach capitalizes on the
- 60 strengths of the sequencing device by generating sequence data for real time analysis to dramatically
- 61 shorten the time required to sequence each sample, and critically, enabling workflows for unbiased
- 62 sequencing to detect novel pathogens and EIDs.

63 Materials and Methods

64 Source Material Quantification and Contrived Sample Preparation

- 65 All experiments were performed using VEEV TC-83 (NR-63), SARS-CoV2 (NR-52286), and
- 66 Human coronavirus (HCoV) 299E (NR-52726). All samples were obtained from BEI Resources. The
- 67 quantity of RNA in viral stocks (source) was determined using GoTaq Probe (Promega) for VEEV
- and SARS-CoV2 and GoTaq RT-qPCR (Promega) for Human coronavirus (HCoV) 229E using
- 69 manufacturer's instructions with an annealing temperature of 55°C. qPCR assays utilized
- 70 commercially available primers for SARS-CoV-2 (Integrated DNA Technologies Catalog
- 71 #10006713) and previously established primer sets for VEEV and HCoV 229E. [11] [12] [13] VEEV
- 72 TC-83 contrived sample was prepared to a working concentration of 1.0×10^{11} Genome Equivalents
- 73 (GE)/mL by adding 149.15 μL VEEV TC-83 stock into 1850.85 μL K₂EDTA human plasma
- 74 (Gender Unspecified Not Filtered, 5mL (HUMANPLK2-0000285). A negative control plasma
- sample was prepared by adding 75.48 μ L PBS to 925.42 μ L human plasma. HCoV 229E contrived
- 76 sample was prepared by adding 149.15 µL HCoV 229E stock into 1850.85 µL SARS-CoV-2 Swab
- 77 Negative VTM, (Discovery Life Sciences) to a working concentration of 4.08E09 GE/mL. A
- 78 negative control VTM sample was prepared by adding 45.70 μL PBS to 454.30 μL SARS-CoV-2
- 79 Swab Negative sample in VTM.

80 **RNA Extraction and host rRNA Depletion**

- 81 RNA from viral stocks, control stocks, and contrived samples were extracted using the Total RNA
- 82 Purification Plus Micro Kit (Norgen #48500) using manufacturer's instructions and adapting the non-
- 83 $\,$ coagulated blood protocol with minor changes of input volume increased to 140 μL from 100 μL and
- 84 Buffer RL increased from 350 µL to 490 µL (3.5 volumes). To deplete host rRNA, Illumina's Ribo-
- 85 Zero Plus rRNA Depletion Kit (#20040526) was used to enzymatically digest ribosomal and globin
- 86 RNA, following the manufacturer's instructions. Purified contrived RNA and depleted contrived
- 87 RNA samples were quantified using GoTaq Probe (Promega) using manufacturer's instructions using
- 88 an annealing temperature of 55°C.

89 Library Preparation and Sequencing

- 90 For testing which library sequencing method worked best, we directly tested Direct RNA (dRNA),
- 91 Direct cDNA (DcRNA), Rapid, and Double stranded cDNA (dscDNA) sequencing methods. Direct
- 92 RNA sequencing was performed by using Direct RNA sequencing kit (SQK-RNA002) with the
- 93 manufacturer's instructions. Starting RNA input of 9 μ L (<500ng) was reverse transcribed using RT
- adapter and Superscript III (Invitrogen 18080044) and RT adapter resulting in an RNA/DNA hybrid.
- 95 Direct cDNA sequencing was performed using Direct cDNA Sequencing kit (SQK-DCS109).
- 96 Briefly, 7.5 µL purified RNA (<100ng) is used to generate first strand cDNA using Maxima H Minus
- 97 Reverse Transcriptase (Thermofisher EP0741) using a poly T strand-switching primer. Synthesis of
- 98 the second strand of cDNA occurred using 2x LongAmp Taq Master Mix (NEB M0287S) before end
- 99 repair and adapter ligation. For Rapid and dscDNA sequencing, RNA ($12 \mu L$) was transcribed using
- 100 Maxima H Minus Double-Stranded cDNA Synthesis Kit (Thermofisher K2561) using random
- hexamers and following the manufacturer's instructions with the minor change of increasing the 1^{st}
- 102 strand enzyme to 2 µL. Rapid sequencing was performed using the Rapid sequencing kit (SQK-103 RAD004) using the manufacturer's instructions. dscDNA libraries were performed using the end
- 103 RAD004) using the manufacturer's instructions. dscDNA libraries were performed using the end 104 repair and adapter ligation of either the Direct cDNA sequencing kit or Ligation sequencing kit
- 105 (SQK-LSK110), following the manufacturer's instructions. Rapid Barcode sequencing kit (SQK-
- 106 RBK004) was used for multiplexing rapid libraries. Ligation sequencing kit (SQK-LSK110) and
- native barcode expansion kit 1-12 (EXP-NBD104) were used for multiplexing dscDNA libraries.
- 108 All bead cleanups were done on a microfuge tube magnetic separation stand (Permagen). Sequencing
- 109 of libraries were performed on Oxford Nanopore MinION Mk1B or Mk1C using R9.4.1 flow cells
- 110 (FLO-MIN106D) or Flongle flow cells (FLO-FLG001) with the Flongle adapter (FLGIntSP). Each
- 111 flow cell was primed and loaded using manufacturer's instructions. Each run used default settings
- and ran for approximately 24 hours.

113 Unbiased cDNA Amplification

- 114 Addition of REPLI-g Whole Transcriptomic Analysis (WTA) Single Cell Kit (Qiagen 150063) to the
- 115 dscDNA and Rapid workflows were examined for increased sensitivity. REPLI-g WTA was used for
- 116 unbiased cDNA amplification with the following modifications. Briefly, for RNA samples selected
- 117 for amplification, double-stranded cDNA was transcribed using random hexamers with the Maxima
- 118 H Minus Double-Stranded cDNA Synthesis Kit and was cleaned using AMPure XP beads. The
- 119 cleaned cDNA was then denatured at 95°C for 3 min, snap chilled on ice, and amplified using
- 120 REPLI-g sc Reaction Buffer and SensiPhi DNA polymerase. Amplified samples underwent an
- 121 AMPure XP bead clean up and digestion using T7 Endonuclease I (NEB M0302L). For effective
- removal of T7 digested fragments, a custom AMPure XP bead solution was made using PEG 8000
- 123 50%(w/v) (Fisher Scientific NC1017553). Once cleaned, library construction was performed using
- 124 the dscDNA or Rapid workflows.

125 Data Analysis

For each sequencing run, passing reads (default threshold of Q8) were concatenated, and quality

127 control (QC) was performed with by removing all reads that map human before aligning to the viral

reference genomes. For validation of viral sequencing and coverage, the target viral genome was

selected (e.g., SARS-CoV-2 reference genome, VEEV NC_001449 reference genome, human

130 coronavirus 229E AF304460.1 reference genome). Reads passing QC were aligned to viral genomes

using minimap2 with default ont parameters. Alignments were analyzed to determine evenness,depth, and total coverage of the target genome for each library preparation method, which was

intended to be used in line with the provisional guidance for sequencing-based diagnostics).

Alignments to the viral genome references were used to generate a consensus sequence, BLAST was

135 used to generated additional coverage and percent identity statistics. A presumptive match criteria

136 threshold for evaluating workflows was set based on alignment with known reference genome

137 sequences with greater than 90% identity over 90% or more of the genome. The threshold was

138 determined.

139 **Results**

140 Library Preparation Method Evaluation

141 We first sought to characterize genome sequence coverage across four sequencing library preparation

142 workflows. Total RNA was extracted from lysates containing SARS-CoV-2 (heat inactivated) and

143 VEEV. The maximum nucleic acid quantity as specified by manufacturer recommendations was then

144 used as input for each of the four library preparation workflows (Direct RNA (dRNA), Direct cDNA

145 (DcRNA), Rapid, and Double stranded cDNA (dscDNA)). Figure 1 shows the resulting coverage

146 across the two genomes for each library preparation method. (Additional statistics are available in

Table S1) The different sequence library preparation workflows produced different levels of
 coverage of the viral genomes. Because the DcDNA and dRNA methods require the use of a poly-

dT primer for reverse transcription, these methods produced a bias for coverage at the 3' end of the

150 genome due to the reliance on the poly-A tail for primer annealing and ligation, respectively. The

dscDNA and Rapid method both utilized a random-hexamer for reverse transcription, reducing the

bias of specific genomic regions and allowing sequencing of any RNA viruses, not just those with a

poly-A tail. As a result, the dscDNA and Rapid methods performed better overall in terms of total

154 genome coverage.

155 When comparing genome sequence coverage between VEEV and SARS-CoV-2, it was apparent that 156 the coronavirus material had lower sequence coverage overall. This discrepancy in read counts could 157 be attributed to lower starting input (~4.23E7 GE SARS-CoV-2 vs. ~8.27E9 GE VEEV). The 158 SARS-CoV-2 material had a higher host background than VEEV based on the abundance of reads 159 mapping to the viral vs. cell culture component of the RNA extracts (data not shown). We 160 hypothesized that, because the SARS-CoV-2 material was heat inactivated, there may have been substantial genome fragmentation and degradation of the SARS-CoV-2 genomes, resulting in lower 161 162 overall read counts and percentage of passing quality reads. To test this, an alternate, non-inactivated coronavirus culture, Human coronavirus 229E (HCoV 229E), was examined in parallel. Following 163 164 library preparation using the dscDNA method, it was apparent that HCoV 229E showed markedly 165 higher genome sequence coverage (Figure 1), as well as higher read count and percentage of passing 166 quality reads compared to SARS-CoV-2 (Table S1). This was the case even as HCoV 229E had a 167 similar percentage of reads mapped to the viral genome as SARS-CoV-2 in the respective sequencing 168 runs. Despite the low quality of RNA derived from the heat inactivated SARS-CoV-2 material, the

169 sequencing results demonstrated clear benefits of the random hexamer based reverse transcription

- 170 methods of dscDNA and Rapid. The Rapid and dscDNA method had greater coverage over the
- 171 genome compared to DcDNA and dRNA. The dRNA methods using VEEV source material
- 172 produced low coverage of the genome, while the DcDNA method produced a mean sequencing depth
- 173 orders of magnitude lower than the Rapid or dscDNA methods using the VEEV source material.
- 174 Next, we sought to evaluate performance across a number of critical metrics for the performance of
- 175 metagenomic sequencing assays across the DcDNA, dRNA, dscDNA, and Rapid sequencing
- 176 workflows. To do this, contrived samples were assembled to mimic human clinical samples. VEEV
- 177 source material was spiked into human plasma prior to RNA extraction and HCoV 229E was spiked
- 178 into remnant clinical viral transport media (VTM) samples. Samples were then extracted and
- sequenced. VEEV samples were sequenced by all four sequencing workflows, while HCoV 229E
- 180 samples were only sequenced using the top two performing workflows (Rapid and dscDNA) to
- 181 conserve sequencing reagents.
- 182 The dscDNA and Rapid methods yield a greater number of reads mapped to VEEV compared to
- 183 DcDNA and dRNA (Figure 2). dRNA had a greater total number of reads compared to DcDNA and
- dscDNA but less mapped VEEV reads. The dcDNA method produced the lowest read count of all
- 185 library preparation methods. The dscDNA and Rapid methods also generated higher quality data
- suitable for use in mapping and database alignments (Figure 3). Similar to the direct sequencing of
- 187 VEEV viral extract, the dRNA method resulted in low mean read depth of the genome from RNA
- 188 extracted from active VEED spiked in human plasma. The DcDNA method using VEEV spiked
- 189 plasma also had relatively low mean read compared to dscDNA and Rapid methods.
- 190 With clear performance benefits apparent for the dscDNA and Rapid methods, we utilized these
- 191 methods to evaluate HCoV 229E detection in a VTM sample background. HCoV 229E was
- sequenced and detected in a similarly robust manner compared to VEEV in terms of read depth
- 193 (Figure 2) and read quality and assessment (Figure 3). Summary metrics for both VEEV and HCoV
- 194 229E spiked samples are shown in Table 1 for the dscDNA and Rapid methods, including non-spiked
- 195 control samples comprised of RNA extracted from plasma or VTM not containing virus. (Additional
- 196 metrics are available in Table S2). The table contains the relative genomic equivalence of viral 197 genomes used in each sample input to workflows based on RT-qPCR within the contrived sample
- 198 indicating the viral load. This value may be an overestimate of certain viral genomic copies,
- especially for HCoV 229E wherein the RT-qPCR target of the N gene falls within a sub-genomic
- transcript that may be in greater abundance than the whole genome in the viral lysates used for this
- study. This sub-genomic transcript at the 3' end of the genome maybe noticeable in Figure 1.
- 202
- 203

206	Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid
	Virus	VEEV	VEEV	229E	229E	None	None	VEEV	VEEV	229E	229E	None	None
207	Matrices	Plasma	Plasma	VTM	VTM	Plasma	VTM	Plasma	Plasma	VTM	VTM	Plasma	VTM
207	Replicate	1	2	1	2	1	1	1	2	1	2	1	1
	GE in total	1.04E+08	1.04E+08	1.33E+09	1.33E+09	0	0	1.04E+08	1.04E+08	1.33E+09	1.33E+09	0	0
• • • •	Mean Depth	937.10	2236.30	734.54	3461.83	0	0	15373.00	7265.00	9688.86	7301.84	0	0
208	Coverage (%, minimap2)	99.97	99.99	100.00	100.00	0	0	99.99	99.99	100.00	100.00	0	0
200	Identity of Coverage (%)	96.34	96.33	99.91	99.91	0	0	96.36	96.35	99.93	99.93	0	0
209	N50	1,209	1,221	1,535	1,962	658	1317	303	280	349	331	217	261
210	Longest Alignment length (Kb)	4.62	4.46	6.11	6.87	0	0	2.07	2.08	3.14	2.61	0	0
	Total Reads	19,094	46,177	575,045	2,411,913	2047	361,490	1,498,299	911,560	3,313,337	2,788,740	26,785	1,536,316
211	Passing Quality Reads (%)	80.22	77.97	35.15	13.94	65.5	28.07	78.84	75.00	66.71	74.25	35.89	65.03
212	Mapped Passed Reads to Virus (%)	69.92	73.00	5.68	17.04	0	0	67.08	57.42	52.22	47.42	0	0
	Passing bp (%)	79.99	76.73	63.75	62.63	65.5	28.07	69.36	60.75	66.88	73.04	35.89	60.26
213	· · · ·												

205 Table 1. Sequencing Summary of Contrived Viral Samples Using dscDNA or Rapid Method

215

216 Assessment of Need for Host RNA Depletion from Contrived Samples

217 Depletion of host RNA within metagenomic samples is commonly used to enrich for viral and other

218 microbial signatures. We examined the effect of host RNA depletion on contrived VEEV samples

219 within a human plasma background. Table 2 summarizes the results from sequencing of RNA

220 recovered following depletion of human ribosomal RNA (cytoplasmic and mitochondrial) and globin

221 RNA (Additional metrics available in Table S3). This included replicate sequencing of the contrived

- samples using both dscDNA and Rapid library prep methods.
- In all cases, the host depletion method used caused a decrease in total number of human reads as
- expected, but the percent of reads passing quality filters and mapping to the viral genome also
- decreased significantly. This may be due to the method used by the depletion kit, wherein target

RNA is enzymatically digested following hybridization by DNA probes complementary to the target

sequence. Based on the N50 and the decrease in longest read within dscDNA method, the enzymatic

digest likely targeted non-specifically to the total RNA. This non-specific cleavage could be related

to the low total RNA input into the reaction or the relatively low abundance of human RNA in the

samples. This method and alternative methods for depletion may be necessary for other sample types

231 with high host background (e.g., whole blood), but the relatively low abundance of human RNA

232 within the plasma and VTM samples does not appear to necessitate host RNA depletion.

233 We utilized centrifuge to assign taxonomical classification to the sequenced reads (Figure 4). There

234 were 2- to 3-log decreases in the VEEV genomic material recovered from the samples that were

235 depleted compared to non-depleted. Meanwhile, human RNA was only depleted by 1- to 2-log. There

236 was very little reduction of human RNA depleted within the plasma sample itself.

Method	dscDNA	dscDNA	dscDNA	Rapid	Rapid	Rapid
Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV
Treatment	None	None	Depleted	None	None	Depleted
GE in total ¹	1.04E+08	1.04E+08	9.50E+07	1.04E+08	1.04E+08	9.50E+07
Post-depletion GE in total	NA	NA	1.60E+07	NA	NA	1.60E+07
Mean Depth	937.10	2236.30	0.73	15,373.00	7265.00	0.03
Coverage (%, minimap2)	99.97	99.99	39.37	99.99	99.99	2.89
Identity of Coverage (%)	96.34	96.33	99.34	96.36	96.35	100.00
N50	1,209	1,221	381	303	280	226
Longest Alignment length (Kb)	4.62	4.46	0.19	2.07	2.08	0.9
Total Reads	19,094	46,177	1,095	1,498,299	911,560	5352
Passing Quality Reads (%)	80.22	77.97	28.95	78.84	75.00	20.59
Mapped Passed Reads to Virus (%)	69.92	73.00	5.36	67.08	57.42	0.18

239 Table 2. Sequencing Summary of Host Depletion from Contrived Viral Samples

240

1 - RNA input to depletion kit is less, all resulting depleted RNA was input for sequencing library

241 Assessment of Sample Multiplexing by Barcoding

242 There are few approaches for sample multiplexing to reduce per sample sequencing costs. Barcoding

for running multiple samples on a single flow cell can reduce time by allowing parallel sample 243

244 preparations and cost by reducing the number of flow cells needed to process multiple samples.

245 However, multiplexing can also reduce sensitivity by producing fewer sequencing reads per samples

or barcode and introduce the potential for cross contamination of sample read pools because of 246

barcode crosstalk. The Rapid method essentially allows the barcodes to be added during tagmentation 247

248 while the dscDNA method allows the use of the Native Barcoding Kit to ligate indexes to each

249 cDNA molecule.

250 We used the 12-plex based barcoding kits to examine multiplexing of the dscDNA and Rapid

methods. Ten of the samples contained duplicate reactions of RNA extracted from human plasma 251

252 spiked with VEEV at multiple concentrations. The last two samples contained RNA extracted from

253 A549 cells and human plasma. Tables 3 and 4 contain the summary results of sequencing using a 12-

254 plex dscDNA method and Rapid method, respectively.

- 255 The sensitivity threshold for positive detection was set at > 90% identify over > 90% of the genomic
- 256 sequence. The multiplex dscDNA method (Table 3) dropped below this threshold with VEEV load at
- 257 1.04E04 GE of VEEV in plasma with coverages at 88% and 75% for the duplicate library
- 258 preparations. The multiplex Rapid method (Table 4) showed a similar drop in coverage at this
- loading but to a greater extent (24% and 34%). (Additional metrics are available in Table S4 and S5 259
- 260 for multiplex dscDNA and Rapid methods, respectively)

261 The total read counts produced by the multiplex dscDNA method at 1.04E8 load was comparable to

the single-plex of the method at the same loading. In addition, the percent of passing reads, 262

- percentage of reads mapped to VEEV, and the mean depth were also comparable. Upon the analysis 263
- 264 of the duty-time record for the multiplex and single-plex of dscDNA method (Figure 5), single-plex

utilization of the available pores appeared to be low. This low utilization provided additional pores 265

266 for sequencing for multiplex of additional dscDNA libraries without decreasing read quality and read

267 number.

- 268 The total number of reads using the Rapid method decreased from millions of reads in the single-plex
- 269 workflow to tens-of-thousands of reads in the multiplex at the same loading. The percentage of
- 270 quality passing reads was higher in the multiplex compared to the single-plex, but percentage of
- 271 mapped reads was lower in the multiplex leading to a reduction in mean depth. Some data was lost
- due to the inability to assign to a barcode (unclassified). Analysis of the duty-time record for the
- 273 multiplex and single-plex Rapid method (Figure 5) had comparable percentage of pores actively
- sequencing, suggesting that the Rapid method in single-plex or multiplex used similar flow cell
- 275 capacity available for sequencing.

277 Table 3. Sequencing Summary of Multiplex (12 samples) of dscDNA Method

Method	dscDNA	dscDNA	dscDNA										
Virus or Sample	VEEV	A549 RNA	Plasma	Unclassified									
GE in total	1.04E+08	1.04E+08	1.04E+06	1.04E+06	1.04E+04	1.04E+04	1.04E+02	1.04E+02	1.04E+00	1.04E+00	NA	NA	NA
Replicate	1	2	1	2	1	2	1	2	1	2	NA	NA	NA
Mean Depth	1099.25	1354.03	8.08	10.47	2.29	1.59	1.13	1.21	1.71	1.73	0.43	1.39	104.46
Coverage (%, minimap2)	99.98	99.99	99.63	99.67	86.82	72.61	65.61	74.01	70.90	77.67	25.44	78.88	99.97
Identity of Coverage (%) ¹	96.35	96.33	96.19	96.32	97.99	98.28	98.97	99.12	98.01	98.19	99.00	98.66	96.30
N50	1574	1410	781	598	571	329	747	470	390	695	1036	520	982
Longest Alignment length	4.85	4.63	3.55	3.48	2.08	2.88	2.21	1.35	2.49	2.23	1.42	2.20	4.22
(Kb)													
Total Reads	18,486	26,217	1,901	3,706	3,818	7,134	2,455	4,633	4,381	3,134	86,795	14,208	72,172
Passing Quality Reads	80.36	81.36	69.59	60.55	54.45	54.74	69.25	63.44	53.71	69.11	89.13	84.13	20.32
(%)													
Mapped Passed Reads to	67.22	66.19	5.06	4.10	1.06	0.44	0.65	0.54	0.68	0.92	0.01	0.13	7.28
Virus (%)													
Passing bp (%)	84.32	84.64	41.51	64.06	7.49	57.53	51.25	72.68	17.01	74.56	83.63	85.16	4.16

1 - Average in cases of multiple mapping from discontinuous coverage

278

279 Table 4. Sequencing Summary of Multiplex (12 samples) of Rapid Method

Method	Rapid	Rapid	Rapid										
Virus or Sample	VEEV	A549 RNA	Plasma	Unclassified									
GE in total	1.04E+08	1.04E+08	1.04E+06	1.04E+06	1.04E+04	1.04E+04	1.04E+02	1.04E+02	1.04E+00	1.04E+00	NA	NA	NA
Replicate	1	2	1	2	1	2	1	2	1	2	NA	NA	NA
Mean Depth	246.63	260.82	2.10	8.50	0.22	0.32	0.33	0.19	0.29	0.56	0.41	0.11	29.96
Coverage (%, minimap2)	99.87	99.98	85.99	99.74	21.95	28.28	27.29	14.76	24.69	45.72	25.92	9.76	99.76
Identity of Coverage (%) ¹	96.34	96.35	98.41	96.41	99.79	99.80	99.45	99.48	99.71	99.52	99.54	99.23	96.33
N50	276	304	238	227	232	226	232	226	222	225	234	227	268
Longest Alignment length	3.15	2.79	1.56	1.81	1.21	1.20	1.10	0.92	0.59	1.71	1.15	0.53	2.37
(Kb)													
Total Reads	35907	32043	64791	28077	41866	30055	143979	46633	83828	15697	57872	26880	181789
Passing Quality Reads	85.64	85.34	86.65	81.28	84.24	82.29	86.37	85.23	83.07	75.55	85.74	84.39	21.95
(%)													
Mapped Passed Reads to	17.66	24.10	0.09	1.01	0.01	0.03	0.01	0.02	0.02	0.08	0.02	0.02	1.66
Virus (%)													
Passing bp (%)	86.72	86.38	86.63	81.12	83.45	81.39	84.18	84.61	82.16	75.36	87.23	84.20	10.20

1 - Average in cases of multiple mapping from discontinuous coverage

281 Assessment of Lower Throughput Flongle

282 We evaluated the flongle flow cell. The flongle has lower throughput and cost compared to the 283 standard flow cell. We evaluated the dscDNA and Rapid method for use on the flongle using RNA 284 extracted from plasma spiked with VEEV. Table 5 shows a summary of sequence results from using 285 flongle in place of a standard flow cell for the dscDNA and Rapid methods. Total read counts were 286 significantly lower for dscDNA and Rapid methods using the flongle compared to the standard flow 287 cell. The dscDNA method had comparable percentage of passing quality reads and mapped reads using the flongle to that of a standard flow cell. The Rapid method using the flongle had a decrease in 288 289 percentage of passing quality of the reads and mapped reads to that of the standard flow cell.

- Both methods showed high inactivity of pores on the flongle with high percentage of usage of
- available pores based on the duty-time report (Figure 7). Interestingly, the low usage of the pores on
- the standard flow cell by dscDNA suggest that the flongle should provide sufficient sequence depth
- to align with the standard flow cell in these samples. The utilization of number of pores on the
- flongle was approximately 32 while the standard flow cell showed early usage at approximately 64
- and falling quickly to 32. However, the increasing inactivation of pores on the flongle quickly
- reduced the capacity for both methods and causing low read counts. This high inactivation rate
- reduced the comparable output of the flongle to the standard flow cell for the dscDNA method.
- 298 Future iterations of the flongle or luck, as loading often is the cause of pore inactivity, may make the
- flongle a future option for low input samples such as plasma or VTM.

300

Table 5. Sequencing Summary of Flongle Use

Method	dscDNA	Rapid
Virus	VEEV	VEEV
GE in total	1.04E+08	1.04E+08
Mean Depth	619.94	1.22
Coverage (%, minimap2)	99.99	70.37
Identity of Coverage (%)	96.32	99.15
N50	1434	208
Longest Alignment length (Kb)	4189	496
Total Reads	16724	4285
Passing Quality Reads (%)	57.21	20.65
Mapped Passed Reads to Virus (%)	66.71	9.27
Passing bp (%)	54.30	4.23

301

302 Assessment of Whole Transcriptome Amplification

303 Because of the low RNA yields contrived VEEV samples in VTM and plasma, we evaluated whole

304 transcriptome amplification (WTA). WTA to increase sequencing material would allow for full

305 utilization of the available pores within a standard flow cell. WTA was examined using a 6-plex

306 barcoding scheme using the native barcoding kit for dscDNA and rapid barcoding kit instead of rapid

307 sequencing kit for the Rapid method. The six samples contained duplicate reactions of RNA

308 extracted from Human plasma spiked with VEEV at decreasing viral load. The genomic equivalency

309 entering the WTA was 8.21E05, E03, and E01.

310 The use of WTA had impacts on both methods. Table 6 and Table 7 contain the sequencing summary

311 for the dscDNA and Rapid methods supplemented with WTA using VEEV, respectively. (Additional

312 metrics are available in Tables S7 and S8). The dscDNA and Rapid method both had increases in

313 total read count compared to the previous multiplex run. WTA greatly increased total read counts for

- 314 dscDNA compared to single-plex while Rapid increase of total read counts was less, most likely due
- 315 to their respective pore usages compared to the previous multiplex and single-plex runs. The
- 316 percentage of passed reads and mapped reads to virus were comparable to previous multiplex runs.
- 317 There was an increase in N50 in both Rapid and dscDNA methods when using WTA suggesting
- 318 potentially longer reads. Both methods also had increased coverage of the genome and mean depth at
- 319 lower VEEV loading. The Rapid method utilizing WTA met threshold (>90% identify over >90% of
- 320 the genome) as low as 8.21E03 GE improving upon the drop at 1.04E04 GE on the previous
- 321 multiplex run without WTA. The dscDNA met threshold for all viral loads tested as low as 8.21E01 322
- GE improving greatly upon the previous multiplex run drop of sensitivity at 1.04E04 GE. Table 8 323
- contains the sequencing summary for dscDNA method supplemented with WTA using HCoV 229E.
- 324 HCoV 229E was tested as low as 2.29E05 GE viral loading resulting in positive threshold values for
- 325 identification.
- 326 Duty-time reports (Figure 8) indicate a high rate of inactivation of pores using the WTA in both
- 327 dscDNA and Rapid compared to multiplex and single-plex methods without WTA. Both methods
- 328 showed initial burst of sequencing and utilization of all available pores until inactive channels
- 329 disrupted productive sequencing. This inactivity was more pronounced in the Rapid method
- 330 compared to the dscDNA methods, which also contributed to lower total read counts for the Rapid
- 331 method. The relatively high activity very early with the dscDNA method combined with WTA
- 332 explains the much higher read count and improvement of coverage and mean depth in samples with
- 333 lower concentration of spiked VEEV into Human plasma. Interestingly, the barcode crosstalk was
- 334 lower compared to the previous multiplex run (See Table S7-S9 for unused and unclassified
- 335 barcodes). This may be due to higher concentration of starting material input to the Rapid Barcoding
- 336 Kit and the Native Barcoding with Ligation Sequencing Kit. The improved sensitivity and potential
- 337 for multiplexing samples (at least 6-plex) makes the use of WTA in conjunction with the Rapid and
- 338 dscDNA methods superior to the methods without WTA.

339 Table 6. Sequencing Summary of Whole Genome Amplification and dscDNA Method using

340 **VEEV (Multiplex of 6 samples)**

Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA
Virus or Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV
GE in total	8.21E+05	8.21E+05	8.21E+03	8.21E+03	8.21E+01	8.21E+01
Replicate	1	2	1	2	1	2
Mean Depth	2954.70	3914.28	150.02	137.55	47.41	66.24
Coverage (%, minimap2)	99.99	99.97	98.34	98.44	90.33	92.42
Identity of Coverage (%)	96.34	96.37	96.29	96.33	96.94	97.70
N50	3376	2940	2734	3476	3483	3496
Longest Alignment length	3.19	2.96	1.84	3.15	1.84	2.86
(Kb)						
Total Reads for a Barcode	98649	139714	136040	108623	82638	120026
Percent of Total Reads in	10.69	15.14	14.74	11.77	8.96	13.01
Run						
Passing Quality Reads	68.51	68.40	69.74	68.21	71.28	68.91
(%)						
Mapped Passed Reads to	25.89	26.83	0.96	1.01	0.48	0.51
Virus (%)						
Passing bp (%)	66.86	66.20	67.02	65.28	68.15	66.83

341

342 Table 7. Sequencing Summary of Whole Genome Amplification and Rapid Method using

343 VEEV (Multiplex of 6 samples)

Method	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid
Virus or Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV
GE in total	8.21E+05	8.21E+05	8.21E+03	8.21E+03	8.21E+01	8.21E+01
Replicate	1	2	1	2	1	2
Mean Depth	5056.20	5176.32	100.84	114.58	5.31	3.62
Coverage (%, minimap2)	99.59	99.27	97.91	97.98	62.48	71.49
Identity of Coverage (%) ¹	96.34	96.34	96.35	96.25	96.97	96.82
N50	2578	2658	2572	2661	2464	2529
Longest Alignment length (Kb)	2.71	2.62	2.10	1.93	1.75	1.89
Total Reads for a Barcode	188566	185313	156451	162121	213392	133602
Percent of Total Reads in Run	15.03	14.77	12.47	12.92	17.01	10.65
Passing Quality Reads (%)	90.06	89.37	89.74	89.05	89.90	89.93
Mapped Passed Reads to Virus (%)	25.43	25.98	0.58	0.60	0.02	0.03
Passing bp (%)	88.52	88.10	88.27	87.40	88.93	89.20

1 - Average in cases of multiple mapping from discontinuous coverage

344

346 Table 8. Sequencing Summary of Whole Genome Amplification and dscDNA Method using

347 HCoV 229E (Multiplex with 6 samples)

Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA
Virus or Sample	229E	229E	229E	229E	229E	229E
GE in total	2.29E+07	2.29E+07	2.29E+06	2.29E+06	2.29E+05	2.29E+05
Replicate	1	2	1	2	1	2
Mean Depth	3566.62	3050.51	1572.42	1562.44	2059.74	1612.87
Coverage (%, minimap2)	99.98	100	99.94	99.92	99.86	99.95
Identity of Coverage (%)	99.89	99.91	99.91	99.92	99.89	99.89
N50	3164	3867	3434	3255	3305	3097
Longest Alignment length	3419	3193	3216	314	2822	2340
(Kb)						
Total Reads for a Barcode	159507	134289	150470	152969	175653	135563
Percent of Total Reads in	13.10	11.03	12.36	12.56	14.42	11.13
Run						
Passing Quality Reads	83.53	78.13	80.41	81.00	79.07	80.52
(%)						
Mapped Passed Reads to	36.50	34.49	18.15	18.32	23.24	23.60
Virus (%)						
Passing bp (%)	83.03	81.77	80.30	80.22	78.02	79.37

348

349 Analysis of Clinical Remnant Samples

350 Clinical remnant samples consisting of respiratory swabbed samples stored in viral transport medium were subjected to the workflow from viral RNA extraction, library preparation, and bioinformatic 351 352 workflow. The clinical samples did not consist of the viruses tested for the validation but are relevant 353 RNA viruses. The majority of detected viral sequences did not rise to the set threshold of $\geq 90\%$ 354 identity over \geq 90% of the genome, nor the minimum working mean depth. The only exception was 355 the detection of human respiratory syncytial virus wildtype strain B1 (RSV) in one of the six 356 multiplexed samples, at 96.25% identity with 99.32% coverage of the genome (Table 9). (Additional 357 information is available in Table S10 and S11). This sample also showed 248.9 mean depth, greater 358 than the working cutoffs of 10 or 15. While RSV was also detected in the other samples, the highest 359 mean depth was 3.09, well below the mean depth cutoff of 10 utilized to avoid false positives due to 360 barcode cross talk, as well as the alternative cutoffs determined be the negative control. This result 361 also highlights the importance of negative controls for the evaluation of potential false positives and 362 appropriate thresholds. Interestingly, after removal of RSV from the results, barcode17 had human 363 metapneumovirus as the next top hit in both coverage (29.04%) and mean depth (0.673), including a 364 percent identity of 92.20% of the covered genome. The detection of human metapneumovirus is the 365 original detection using current methods. Barcode 21, after removal of RSV, has a Rhinovirus 366 detection with two genomes at coverage of 17.58% and 16.05% with low mean depth at 0.23 and 367 6.71, respectively. HRV89 was detected with higher mean depth but marginally lower coverage 368 percent identity of 79.79%.

369

372 Table 9. Clinical Remnant Sample Results with WTA assisted dscDNA method

Bioinformatic Ana	alysis Call	Sample Key									
Organism	Metric	hMPV	Influenza A	Parain- fluenza	SARS- CoV-2	Rhinovirus	RSV	Negative	Positive (GFP		
Human respiratory syncytial virus	Coverage	37.79%	24.63%	20.30%	24.47%	32.41%	99.32%	38.38%	6.44%		
wildtype strain B1	Depth	3.08	2.39	1.03	1.27	1.10	249.00	2.34	0.16		
Human metapneumovirus	Coverage	29.04%	NA	NA	6.29%	NA	NA	NA	NA		
1solate CAN97- 83	Depth	0.67			0.06						
Human rhinovirus 89	Coverage	NA	NA	NA	9.16%	16.05%	NA	NA	NA		
(HRV89)	Depth				0.12	4.13					
Phinamirus C4	Coverage	NA			NA	17.58%					
Rhinovirus C4	Depth	NA	NA	NA	NA	0.23	NA	NA	NA		
Respiratory	Coverage	NA	NA		NA	NA	13.59%		NA		
syncytial virus	Depth	NA	NA	NA	NA	NA	0.16	NA			

373

374 1 Discussion

375 Potential Time from Sample Extraction to Sequencing Results

376 Reducing the time required for sample preparation and analysis for RNA or cDNA sequencing are 377 important factors for public health utilization. The average time required to generate a single sample library (1-plex) using our unbiased workflow is 9 hrs from raw RNA to loading the MinION flowcell 378 379 (Figure 9). Multiplexing (6-plex) on average increases each segment of the hands-on time by 15 min, 380 while not affecting the incubation time except for End Repair and Ligation. To multiplex, samples 381 must have a unique barcode ligated before continuing, resulting in a second ligation reaction and 382 bead cleanup. While this workflow is longer than that of standard workday, there are safe stopping 383 points can be found throughout our workflow as indicated in Figure 9 with an asterisk to break it over 384 multiple days.

- Another limiting factor in sequence analysis is the amount of time needed to generate the necessary 385 386 sequence data to identify a potential pathogen within a sample. The process of a DNA sequencing run can take multiple days to complete on high throughput instruments. Sequencing runs used in this 387 388 study were generally conducted for 22 hours to maximize sequence data capture. To evaluate whether 389 the full 22 hours was needed for viral identification, we evaluated the viral genome coverage and 390 read depth over time. Figure 10 shows key viral identification metrics from a contrived VEEV 391 sample in plasma (1.95E03 GE/mL) following WGA in conjunction with the dscDNA method. 392 Percent identity based on a consensus generated by the mapped reads and Blast+ indicated that the 393 lowest identity for any covered portion was 97.25%. 'Mapped Coverage' measured by minmap2
- rising above 90% by 4.25 hrs and maxing at 92.4%, while blast results showed coverage rising to
- 395 90% by 2.5 hrs and hitting a maximum of 95%. Based on the 'Duty time' record in Figure 8, these

396 were achieved while the capacity of active sequencing pores was still greater than 50% of the flow

- 397 cell and two-thirds from initiation of the run. This suggests the potential to shorten sequencing run
- 398 times to < 6 hours depending on the nature of the sample.

399 Implementing metagenomic assays in clinical laboratories

- 400 This study illustrates the potential of metagenomic analysis to public health labs. While the viruses
- 401 used in this study could be detected by PCR approaches in a rapid and straightforward manner,
- 402 targeted detection would require a priori knowledge of pathogen present or potentially expansive
- 403 screening using viral detection panels. In the case of a novel, emerging, or uncommon viral pathogen,
- 404 PCR may fail to identify the agent entirely. This is common in the case of viral sepsis, where a large
- 405 proportion of cases result in a failure to identify the etiological agent [19]. Thus, it is critical to have a
- 406 unbiased, metagenomic method capable of identifying novel, emerging, and rare viral threats
- 407 compatible with widespread utilization in clinical and public health laboratories.
- 408 This approach does not utilize host RNA depletion. Not only did host RNA depletion not improve the
- 409 relative proportion of viral sequences, but the method also used actually decreased the amount of
- 410 viral signature in the sample. This may be due to the relatively low amount of RNA present in these
- 411 samples and the potential for non-specific activity of the enzymatic digestion approach used. The
- 412 clinical sample types used in this study were also likely responsible for the low host RNA
- 413 background. VTM and plasma have lower host background than other sample types, such as whole
- 414 blood. The application of a genome amplification step supports this observation in that, even
- 415 following amplification, host background does not appear to overwhelm the viral genome signature
- 416 within the sample, even at relatively low viral titers.
- 417 The method described herein does pose limitations in respect to widespread clinical laboratory
- 418 implementation. While the molecular methods are not onerous, the workflow remains reasonably
- 419 labor intensive. RNA extractions may be readily automated, and other methods have illustrated
- 420 approaches for automation of nanopore sequencing library preparation [20,21]. Future development
- 421 of automated for this method could streamline the workflow and allow higher-throughput analysis
- 422 based on sample throughput needs. Further optimization could also shorten the amount of time
- 423 required for DNA sequencing. While this study generally utilized 16-24h sequencing runs, it was 424
- clear that the majority of DNA sequencing was completed in the initial few hours following
- 425 initialization. Further evaluation may reveal shorter sequencing durations that are sufficient to
- 426 capture viral signature detection without risking false negatives.
- 427 This method utilizing molecular barcodes to permit multiplexing. This approach has been previously 428 shown to carry some risk of misattribution of barcodes leading to the risk of false positives in one 429 sample due to viral signatures in a different sample in the same sequencing run [5]. While we did 430 observe evidence of barcode "cross-talk," it was insufficient to lead to false positive detections in 431 negative control samples, even when samples within the same sequencing run had extremely high 432 titers. The potential for barcode cross-talk should be closely monitored in future studies, however, to 433 identify conditions that lead to sufficient cross contamination to lead to potential false positive 434 detection. It is likely that if the high accuracy (HAC) basecaller or alternative highly accurate 435 basecallers can be used the assignment of barcode bin will also improve. Currently, the HAC cannot 436 process reads at a rate to keep up with generation while the fast basecaller can. Crosstalk between 437 barcodes is also likely to improve as ONT iterates barcode length and sequence and R10 flow-cell
- 438 iteration with related chemistries.

- 439 Ultimately, before a metagenomic analysis approach can be utilized in clinical laboratories, a more
- 440 extensive method validation is needed. This process will better establish key assay metrics including
- 441 sensitivity, specificity, limits-of-detection, and reproducibility. Further analysis should also focus on
- 442 clinical samples to identify any confounding issues associated with the use of mock clinical samples.

443 Conclusions

- 444 We report an optimal workflow for the unbiased detection of RNA viruses in common clinical
- 445 matrices. This workflow can support multiplex analysis of up to six samples with approximately 9 (1-
- 446 plex) to 11 (6-plex) hours of sample preparation, price ranging from \$750 (single-plex) to \$1565 (six-
- 447 plex), followed by a 10-24 hour sequencing run. The assay can detect viral genomes extracted from
- 448 human plasma or VTM following a nasal/throat swab with as little as 1.95E03 GE/mL.
- 449 Bioinformatics analysis is currently tailored toward target pathogens but is readily scalable to a pan-
- 450 viral assessment to enable unbiased viral signature detection, including homology assessment to
- 451 identify novel or emerging variants. This data supports the implementation of a sensitive, medium
- 452 throughput assay capable of unbiased detection of clinical threats in public health laboratories.

453 Additional Requirements

For additional requirements for specific article types and further information please refer to "Article types" on every Frontiers journal page.

456 **Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.

459 Author Contributions

- 460 All authors have read and approved the manuscript. Conceptualization: ADK, KLT, MBS, FCH.
- 461 Data curation: ADK, MBS, NCK. Laboratory analysis: ANS, NCK, MCM, ADK, LWA. Funding
- 462 acquisition: ADK, FCH, KLT. Data analysis: ADK, ANS, MBS, NCK, KLT, FCH. Project
- 463 administration: ADK, FCH. Writing original draft: ADK, ANS, MBS, NCK, FCH. Writing –
- 464 review & editing: ADK, ANS, MBS, NCK, LWA, MCM, KLT, FCH.

465 Funding

466 This work was supported by the Centers for Disease Control and Prevention's investments to combat 467 antibiotic resistance under contract number 75D30121C12250.

468 Acknowledgments

- 469 The authors would like to thank Leslie Parke for oversight and project management for this effort.
- 470 The authors would also like to thank Jim Gibson for his assistance creating the workflow figure and
- 471 Maddie Pont for her technical review. This work appears in the preprint .

472 1 Data Availability Statement

- 473 The datasets generated during this study for this study can be found in our NCBI BioProject
- 474 [Update].

475 List of abbreviations [Update]

- 476 DNA: Deoxyribonucleic Acid
- 477 cDNA: Copy DNA
- 478 dcDNA: Direct Copy DNA
- 479 DscDNA: Double Stranded cDNA
- 480 EID: Emerging infectious Diseases
- 481 GE: Genome Equivalents
- 482 HAC: High Accuracy Basecalling
- 483 HCoV: Human CoronaVirus
- 484 QC: Quality Control
- 485
- 486 qPCR: Quantitative Polymerase Chain Reaction
- 487 RNA: Ribonucleic Acid
- 488 dRNA: Direct RNA
- 489 rRNA: Ribosomal RNA
- 490 RT: Reverse Transcription
- 491 VEEV: Venezuelan Equine Encephalitis Virus
- 492 VTM: Viral Transport Media
- 493 WTA: Whole Transcriptome Amplification

494 **2 References** [Need review]

- 495 [1] N. Sapoval, M. Mahmoud, M. Jochum, Y. Liu, R.A.L. Elworth, Q. Wang, D. Albin, H.
- 496 Ogilvie, M.D. Lee, S. Villapol, K. Hernandez, I.M. Berry, J. Foox, A. Beheshti, K. Ternus, K.
- 497 Aagaard, D. Posada, C. Mason, F.J. Sedlazeck, T.J. Treangen, Hidden genomic diversity of SARS-
- 498 CoV-2: implications for qRT-PCR diagnostics and transmission, Genome Res. (2021)
- 499 gr.268961.120. https://doi.org/10.1101/gr.268961.120.
- 500 [2] R. Schlaberg, C.Y. Chiu, S. Miller, G.W. Procop, G. Weinstock, the Professional Practice
- 501 Committee and Committee on Laboratory Practices of the American Society for Microbiology, the
- 502 Microbiology Resource Committee of the College of American Pathologists, Validation of
- 503 Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection, Arch. Pathol.
- 504 Lab. Med. 141 (2017) 776–786. https://doi.org/10.5858/arpa.2016-0539-RA.

505 [3] R.R. Miller, V. Montoya, J.L. Gardy, D.M. Patrick, P. Tang, Metagenomics for pathogen 506 detection in public health, Genome Med. 5 (2013) 81. https://doi.org/10.1186/gm485.

507 [4] K. Bibby, Metagenomic identification of viral pathogens, Trends Biotechnol. 31 (2013) 275– 508 279. https://doi.org/10.1016/j.tibtech.2013.01.016.

- 509 [5] Y. Xu, K. Lewandowski, S. Lumley, S. Pullan, R. Vipond, M. Carroll, D. Foster, P.C.
- 510 Matthews, T. Peto, D. Crook, Detection of Viral Pathogens With Multiplex Nanopore MinION
- 511 Sequencing: Be Careful With Cross-Talk, Front. Microbiol. 9 (2018).
- 512 https://www.frontiersin.org/article/10.3389/fmicb.2018.02225 (accessed May 31, 2022).
- 513 [6] F.C. Hewitt, S.L. Guertin, K.L. Ternus, K. Schulte, D.R. Kadavy, Toward Rapid Sequenced-
- 514 Based Detection and Characterization of Causative Agents of Bacteremia, BioRxiv. (2017) 162735.
- 515 https://doi.org/10.1101/162735.
- 516 [7] H.P. McLaughlin, J.V. Bugrysheva, A.B. Conley, C.A. Gulvik, B. Cherney, C.B. Kolton,
- 517 C.K. Marston, E. Saile, E. Swaney, D. Lonsway, A.S. Gargis, T. Kongphet-Tran, C. Lascols, P.
- 518 Michel, J. Villanueva, A.R. Hoffmaster, J.E. Gee, D. Sue, Rapid Nanopore Whole-Genome
- 519 Sequencing for Anthrax Emergency Preparedness, Emerg. Infect. Dis. 26 (2020) 358–361.
- 520 https://doi.org/10.3201/eid2602.191351.
- 521 [8] J.A. Russell, B. Campos, J. Stone, E.M. Blosser, N. Burkett-Cadena, J.L. Jacobs, Unbiased
 522 Strain-Typing of Arbovirus Directly from Mosquitoes Using Nanopore Sequencing: A Field-forward
 523 Biosurveillance Protocol, Sci. Rep. 8 (2018) 5417. https://doi.org/10.1038/s41598-018-23641-7.
- 524 [9] M.R. Lindberg, S.E. Schmedes, F.C. Hewitt, J.L. Haas, K.L. Ternus, D.R. Kadavy, B.
- 525 Budowle, A Comparison and Integration of MiSeq and MinION Platforms for Sequencing Single
- 526 Source and Mixed Mitochondrial Genomes, PLOS ONE. 11 (2016) e0167600.
- 527 https://doi.org/10.1371/journal.pone.0167600.
- 528 [10] CDCgov/SARS-CoV-2_Sequencing, Centers for Disease Control and Prevention, 2021.
 529 https://github.com/CDCgov/SARS-CoV-2_Sequencing (accessed January 12, 2021).
- 530 [11] M.W. Eshoo, C.A. Whitehouse, S.T. Zoll, C. Massire, T.-T.D. Pennella, L.B. Blyn, R.
- 531 Sampath, T.A. Hall, J.A. Ecker, A. Desai, L.P. Wasieloski, F. Li, M.J. Turell, A. Schink, K. Rudnick,
- 532 G. Otero, S.C. Weaver, G.V. Ludwig, S.A. Hofstadler, D.J. Ecker, Direct broad-range detection of
- alphaviruses in mosquito extracts, Virology. 368 (2007) 286–295.
- 534 https://doi.org/10.1016/j.virol.2007.06.016.
- 535 [12] A. Vina-Rodriguez, M. Eiden, M. Keller, W. Hinrichs, M.H. Groschup, A Quantitative Real-
- 536 Time RT-PCR Assay for the Detection of Venezuelan equine encephalitis virus Utilizing a Universal
- 537 Alphavirus Control RNA, BioMed Res. Int. 2016 (2016) 8543204.
- 538 https://doi.org/10.1155/2016/8543204.
- 539 [13] Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in
- 540 differentiated primary human bronchial epithelial cells | American Journal of Physiology-Lung
 541 Cellular and Molecular Physiology, (n.d.).
- 542 https://journals.physiology.org/doi/full/10.1152/ajplung.00374.2020 (accessed May 26, 2022).

- 543 [14] H. Li, New strategies to improve minimap2 alignment accuracy, Bioinformatics. 37 (2021)
- 544 4572–4574. https://doi.org/10.1093/bioinformatics/btab705.
- 545 [15] H. Li, Minimap2: pairwise alignment for nucleotide sequences, Bioinformatics. 34 (2018) 546 3094–3100. https://doi.org/10.1093/bioinformatics/bty191.
- 547 [16] C. Camacho, G. Coulouris, V. Avagyan, N. Ma, J. Papadopoulos, K. Bealer, T.L. Madden,
- 548 BLAST+: architecture and applications, BMC Bioinformatics. 10 (2009) 421.
- 549 https://doi.org/10.1186/1471-2105-10-421.
- 550 [17] A.L. Greninger, S.N. Naccache, S. Federman, G. Yu, P. Mbala, V. Bres, D. Stryke, J.
- 551 Bouquet, S. Somasekar, J.M. Linnen, R. Dodd, P. Mulembakani, B.S. Schneider, J.-J. Muyembe-
- 552 Tamfum, S.L. Stramer, C.Y. Chiu, Rapid metagenomic identification of viral pathogens in clinical
- 553 samples by real-time nanopore sequencing analysis, Genome Med. 7 (2015) 99.
- 554 https://doi.org/10.1186/s13073-015-0220-9.
- 555 [18] P.J. McMurdie, S. Holmes, phyloseq: An R Package for Reproducible Interactive Analysis
- and Graphics of Microbiome Census Data, PLOS ONE. 8 (2013) e61217.
- 557 https://doi.org/10.1371/journal.pone.0061217.
- 558 [19] G.-L. Lin, J.P. McGinley, S.B. Drysdale, A.J. Pollard, Epidemiology and Immune
- 559 Pathogenesis of Viral Sepsis, Front. Immunol. 9 (2018) 2147.
- 560 https://doi.org/10.3389/fimmu.2018.02147.
- 561 [20] I. Raymond-Bouchard, C. Maggiori, L. Brennan, I. Altshuler, J.M. Manchado, V. Parro, L.G.
- 562 Whyte, Assessment of Automated Nucleic Acid Extraction Systems in Combination with MinION
- Sequencing As Potential Tools for the Detection of Microbial Biosignatures, Astrobiology. (2022).
 https://doi.org/10.1089/ast.2020.2349.
- 565 [21] J.F. Hess, T.A. Kohl, M. Kotrová, K. Rönsch, T. Paprotka, V. Mohr, T. Hutzenlaub, M.
- 566 Brüggemann, R. Zengerle, S. Niemann, N. Paust, Library preparation for next generation sequencing:
- 567 A review of automation strategies, Biotechnol. Adv. 41 (2020) 107537.
- 568 https://doi.org/10.1016/j.biotechadv.2020.107537.
- 569
- 570
- 571
- 572
- 573 Figures, tables and additional files
- 574

575 Figure 1.

576



Figure 1. Coverage of the viral RNA genomes based on depth of read alignment.

577



Figure 2. Passed and failed reads states of the difference sequencing workflows for contrived viral samples.



588



Figure 4. Effect of Depletion on Centrifuge Read Counts to Different Taxonomy.



Figure 5. Duty time record of dscDNA and Rapid Single-plex and Multiplex (Pore-Scan)

591



Figure 6. Duty Time report from dscDNA and Rapid loaded on a flongle.

592



Figure 7. dscDNA or Rapid multiplex with and without WGA





Figure 8. Whole Genome Amplification and dscDNA Method with HCoV 229E and VEEV indicating the Coverage and Identity of Mapped Reads Generated During the Run

597